Novavax [NVAX] Soars On Swine Flu Vaccine

[wsj.com]
Novavax Soars As Swine Flu Puts Focus On Multi-Strain Vaccine
NEW YORK (Dow Jones)--Shares of Novavax Inc. (NVAX) on Monday traded up at more than twice last week's closing price as investors were drawn to the pharmaceutical company that has developed a multi-strain flu vaccine, which may help with future cases of flu outbreaks or pandemics.

The vaccine has yet to be approved by the Food and Drug Administration, meaning there aren't any chances for the drug to be released for commercial distribution yet. However, in case of a pandemic or outbreak, the government could call on the company to produce the drug on an emergency basis to help with the latest outbreak of swine flu in Mexico and recent cases in the U.S., an analyst from Rodman & Renshaw said.

In recent trading, shares of the company more than doubled to $3.11. The stock earlier rose to a 52-week high of $3.88. Shares of the company, which had a market capitalization of $56 million as of Friday, have more than doubled in the last three months.